|Increased autoantibodies against oxidized low-density lipoprotein in coronary circulation in patients with coronary spastic angina.|
|PMID: 11269779 Owner: NLM Status: MEDLINE|
|Oxidized low-density lipoproteins are important in the progression of atherosclerosis. Autoantibodies against malondialdehyde-modified low-density lipoproteins have been reported to be predictive of the progression of atherosclerosis. This study sought to examine whether plasma levels of autoantibodies against oxidized low-density lipoprotein increase in the coronary circulation in patients with coronary spastic angina. The authors examined plasma antioxidized low-density lipoprotein antibody levels (activity unit values (AcU)/mL) simultaneously in the coronary sinus and the aortic root in 20 patients with coronary spastic angina, 23 patients with stable exertional angina, and 15 control subjects by measuring plasma levels of immunoglobulin G (IgG) autoantibodies against malondialdehyde-modified low-density lipoproteins by enzyme-linked immunosorbent assay. The plasma antioxidized low-density lipoprotein antibody levels (AcU/mL) in the coronary sinus increased in coronary spastic angina (38 +/- 16) compared with stable exertional angina (23 +/- 7) and control subjects (20 +/- 6) (p < or = 0.0001). The levels (AcU/mL) in the aortic root also increased in coronary spastic angina (33 +/- 12) compared with stable exertional angina (23 +/- 7) and control subjects (20 +/- 6) (p < 0.005). Furthermore, the coronary sinus-arterial differences of the levels (AcU/mL) were also higher in coronary spastic angina (5 +/- 9) than in stable exertional angina (0 +/- 6) and healthy subjects (-1 +/- 5) (p < 0.05). The generation of malondialdehyde-modified low-density lipoproteins is reported to be associated with atherothrombosis. These findings suggest that elevated levels of autoantibodies against malondialdehyde-modified oxidized low-density lipoproteins in coronary circulation are associated with the development of atherothrombosis from the progression of atherosclerosis rather than with the extent of coronary atherosclerosis in patients with coronary spastic angina.|
|H Ogawa; H Soejima; K Takazoe; S Miyamoto; I Kajiwara; H Shimomura; T Sakamoto; M Yoshimura; K Kugiyama; M Kimura; H Yasue|
Related Documents :
|9550499 - Cholesterol lowering in the management of coronary artery disease: the clinical implica...
10712399 - Cholesterol-lowering treatment is associated with improvement in coronary vascular remo...
8775549 - Changes in apolipoproteins during the acute phase of kawasaki disease.
11828189 - Effect of controlling hypercholesterolemia on myocardial ischemia.
15680709 - Statins decrease perioperative cardiac complications in patients undergoing noncardiac ...
15771919 - Electrocardiographic events and cholesterol reduction with pravastatin in patients with...
313189 - Perioperative myocardial infarction associated with coronary artery bypass graft surger...
2437339 - Evaluation of left ventricular residual function using postextrasystolic potentiation. ...
9842289 - Cognitive appraisal and cardiac risk reduction behavior following coronary angioplasty.
|Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't|
|Title: Angiology Volume: 52 ISSN: 0003-3197 ISO Abbreviation: Angiology Publication Date: 2001 Mar|
|Created Date: 2001-03-27 Completed Date: 2001-04-05 Revised Date: 2006-11-15|
Medline Journal Info:
|Nlm Unique ID: 0203706 Medline TA: Angiology Country: United States|
|Languages: eng Pagination: 167-74 Citation Subset: IM|
|Department of Cardiovascular Medicine, Kumamoto University School of Medicine, Kumamoto City, Japan. email@example.com|
|APA/MLA Format Download EndNote Download BibTex|
administration & dosage,
Angina Pectoris, Variant / blood, diagnosis, immunology*
Autoantibodies / immunology*
Biological Markers / blood
Coronary Circulation / immunology*
Enzyme-Linked Immunosorbent Assay
Immunoglobulin G / immunology
Lipoproteins, LDL / immunology*
Malondialdehyde / immunology
Nitroglycerin / administration & dosage, diagnostic use
Vasodilator Agents / administration & dosage, diagnostic use
|0/Autoantibodies; 0/Biological Markers; 0/Immunoglobulin G; 0/Lipoproteins, LDL; 0/Vasodilator Agents; 51-84-3/Acetylcholine; 542-78-9/Malondialdehyde; 55-63-0/Nitroglycerin|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Comparative efficacy of primary angioplasty with stent implantation and thrombolysis in restoring ba...
Next Document: Microalbuminuria, pulse pressure, left ventricular hypertrophy, and myocardial ultrasonic tissue cha...